Cell cycle-based purging of lymphoma cells from bone marrow harvests using radioiodinated 5-iodo-2'-deoxyuridine

Martin H. Schneiderman, John D. Jackson, Shantaram S Joshi, Laurel Clark-Pierce, Barbara J. Murphy, G. Sue Schneiderman

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Minimal residual disease in lymphoma patients is a major problem in the clinical management of their cancer. High-dose chemotherapy followed by autologous bone marrow transplantation has been used to treat the disease. However, residual lymphoma may be reintroduced along with the marrow if it is present in the bone marrow harvest. In this report we describe results of experiments testing the efficacy of 5-[ 125 I]-iodo-2'-deoxyuridine ( 125 IdU) for purging murine RAW117 large cell lymphoma cells (Joshi et al., Oncology 44, 180-185, 1987; Cancer Res. 47, 3551-3557, 1987) from bone marrow in a relevant animal model. Donor BALB/c mice were injected with murine RAWll7 cells and euthanized on day 13, and their bone marrow that had been contaminated with tumor cells was harvested and treated in vitro with 125 IdU or nonradioactive 127 IdU (control). Nine of l0 mice receiving 127 IdU-treated bone marrow contaminated with tumor cells died at an average of 17 days after injection. In comparison, 9 of 10 mice injected with 125 IdU-treated bone marrow contaminated with tumor cells were still alive after 82 days. In addition, the 125 IdU treatment did not diminish the formation of hematopoietic progenitor cell colonies in normal mouse and human peripheral blood stem cells.

Original languageEnglish (US)
Pages (from-to)147-154
Number of pages8
JournalRadiation Research
Volume149
Issue number2
DOIs
StatePublished - Jan 1 1998

Fingerprint

purging
Idoxuridine
bone marrow
Bone Marrow Cells
Lymphoma
Deoxyuridine
Cell Cycle
Bone Marrow
cycles
mice
cells
tumors
Neoplasms
cancer
transplantation
blood cells
animal models
Autologous Transplantation
stem cells
Residual Neoplasm

ASJC Scopus subject areas

  • Biophysics
  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

Schneiderman, M. H., Jackson, J. D., Joshi, S. S., Clark-Pierce, L., Murphy, B. J., & Schneiderman, G. S. (1998). Cell cycle-based purging of lymphoma cells from bone marrow harvests using radioiodinated 5-iodo-2'-deoxyuridine. Radiation Research, 149(2), 147-154. https://doi.org/10.2307/3579924

Cell cycle-based purging of lymphoma cells from bone marrow harvests using radioiodinated 5-iodo-2'-deoxyuridine. / Schneiderman, Martin H.; Jackson, John D.; Joshi, Shantaram S; Clark-Pierce, Laurel; Murphy, Barbara J.; Schneiderman, G. Sue.

In: Radiation Research, Vol. 149, No. 2, 01.01.1998, p. 147-154.

Research output: Contribution to journalArticle

Schneiderman, MH, Jackson, JD, Joshi, SS, Clark-Pierce, L, Murphy, BJ & Schneiderman, GS 1998, 'Cell cycle-based purging of lymphoma cells from bone marrow harvests using radioiodinated 5-iodo-2'-deoxyuridine', Radiation Research, vol. 149, no. 2, pp. 147-154. https://doi.org/10.2307/3579924
Schneiderman, Martin H. ; Jackson, John D. ; Joshi, Shantaram S ; Clark-Pierce, Laurel ; Murphy, Barbara J. ; Schneiderman, G. Sue. / Cell cycle-based purging of lymphoma cells from bone marrow harvests using radioiodinated 5-iodo-2'-deoxyuridine. In: Radiation Research. 1998 ; Vol. 149, No. 2. pp. 147-154.
@article{b488b739e0c54954a3c4d5bc87701f46,
title = "Cell cycle-based purging of lymphoma cells from bone marrow harvests using radioiodinated 5-iodo-2'-deoxyuridine",
abstract = "Minimal residual disease in lymphoma patients is a major problem in the clinical management of their cancer. High-dose chemotherapy followed by autologous bone marrow transplantation has been used to treat the disease. However, residual lymphoma may be reintroduced along with the marrow if it is present in the bone marrow harvest. In this report we describe results of experiments testing the efficacy of 5-[ 125 I]-iodo-2'-deoxyuridine ( 125 IdU) for purging murine RAW117 large cell lymphoma cells (Joshi et al., Oncology 44, 180-185, 1987; Cancer Res. 47, 3551-3557, 1987) from bone marrow in a relevant animal model. Donor BALB/c mice were injected with murine RAWll7 cells and euthanized on day 13, and their bone marrow that had been contaminated with tumor cells was harvested and treated in vitro with 125 IdU or nonradioactive 127 IdU (control). Nine of l0 mice receiving 127 IdU-treated bone marrow contaminated with tumor cells died at an average of 17 days after injection. In comparison, 9 of 10 mice injected with 125 IdU-treated bone marrow contaminated with tumor cells were still alive after 82 days. In addition, the 125 IdU treatment did not diminish the formation of hematopoietic progenitor cell colonies in normal mouse and human peripheral blood stem cells.",
author = "Schneiderman, {Martin H.} and Jackson, {John D.} and Joshi, {Shantaram S} and Laurel Clark-Pierce and Murphy, {Barbara J.} and Schneiderman, {G. Sue}",
year = "1998",
month = "1",
day = "1",
doi = "10.2307/3579924",
language = "English (US)",
volume = "149",
pages = "147--154",
journal = "Radiation Research",
issn = "0033-7587",
publisher = "Radiation Research Society",
number = "2",

}

TY - JOUR

T1 - Cell cycle-based purging of lymphoma cells from bone marrow harvests using radioiodinated 5-iodo-2'-deoxyuridine

AU - Schneiderman, Martin H.

AU - Jackson, John D.

AU - Joshi, Shantaram S

AU - Clark-Pierce, Laurel

AU - Murphy, Barbara J.

AU - Schneiderman, G. Sue

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Minimal residual disease in lymphoma patients is a major problem in the clinical management of their cancer. High-dose chemotherapy followed by autologous bone marrow transplantation has been used to treat the disease. However, residual lymphoma may be reintroduced along with the marrow if it is present in the bone marrow harvest. In this report we describe results of experiments testing the efficacy of 5-[ 125 I]-iodo-2'-deoxyuridine ( 125 IdU) for purging murine RAW117 large cell lymphoma cells (Joshi et al., Oncology 44, 180-185, 1987; Cancer Res. 47, 3551-3557, 1987) from bone marrow in a relevant animal model. Donor BALB/c mice were injected with murine RAWll7 cells and euthanized on day 13, and their bone marrow that had been contaminated with tumor cells was harvested and treated in vitro with 125 IdU or nonradioactive 127 IdU (control). Nine of l0 mice receiving 127 IdU-treated bone marrow contaminated with tumor cells died at an average of 17 days after injection. In comparison, 9 of 10 mice injected with 125 IdU-treated bone marrow contaminated with tumor cells were still alive after 82 days. In addition, the 125 IdU treatment did not diminish the formation of hematopoietic progenitor cell colonies in normal mouse and human peripheral blood stem cells.

AB - Minimal residual disease in lymphoma patients is a major problem in the clinical management of their cancer. High-dose chemotherapy followed by autologous bone marrow transplantation has been used to treat the disease. However, residual lymphoma may be reintroduced along with the marrow if it is present in the bone marrow harvest. In this report we describe results of experiments testing the efficacy of 5-[ 125 I]-iodo-2'-deoxyuridine ( 125 IdU) for purging murine RAW117 large cell lymphoma cells (Joshi et al., Oncology 44, 180-185, 1987; Cancer Res. 47, 3551-3557, 1987) from bone marrow in a relevant animal model. Donor BALB/c mice were injected with murine RAWll7 cells and euthanized on day 13, and their bone marrow that had been contaminated with tumor cells was harvested and treated in vitro with 125 IdU or nonradioactive 127 IdU (control). Nine of l0 mice receiving 127 IdU-treated bone marrow contaminated with tumor cells died at an average of 17 days after injection. In comparison, 9 of 10 mice injected with 125 IdU-treated bone marrow contaminated with tumor cells were still alive after 82 days. In addition, the 125 IdU treatment did not diminish the formation of hematopoietic progenitor cell colonies in normal mouse and human peripheral blood stem cells.

UR - http://www.scopus.com/inward/record.url?scp=0031932654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031932654&partnerID=8YFLogxK

U2 - 10.2307/3579924

DO - 10.2307/3579924

M3 - Article

VL - 149

SP - 147

EP - 154

JO - Radiation Research

JF - Radiation Research

SN - 0033-7587

IS - 2

ER -